Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis

Description

This study will be a prospective randomized study to evaluate the effect of tranexamic acid (TXA) use on intraoperative and postoperative outcomes among patients undergoing rhinoplasty by two Facial Plastic surgeons at Vanderbilt. Outcomes will include intra- and post-operative bleeding and postoperative bruising and swelling.

Conditions

Surgery, Postoperative Blood Loss

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will be a prospective randomized study to evaluate the effect of tranexamic acid (TXA) use on intraoperative and postoperative outcomes among patients undergoing rhinoplasty by two Facial Plastic surgeons at Vanderbilt. Outcomes will include intra- and post-operative bleeding and postoperative bruising and swelling.

Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis

Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis

Condition
Surgery
Intervention / Treatment

-

Contacts and Locations

Nashville

Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults at least 18 years of age who elect to undergo cosmetic or functional open primary rhinoplasty with osteotomies (repositioning the nasal bones) by Drs. Yang or Patel at VUMC.
  • * No other facial plastics procedure nor sinus surgery performed simultaneously
  • * Lack all the below Exclusion Criteria
  • * Known allergy to TXA (tranexamic acid)
  • * Intracranial bleeding
  • * Known defective color vision
  • * History of venous or arterial thromboembolism
  • * Active thromboembolic disease
  • * Severe renal impairment (diagnosis of chronic kidney disease)
  • * History of coagulation disorder
  • * Known thrombocytopenia (platelets \<150,000)
  • * Current use of anticoagulant (blood thinner)
  • * Uncontrolled DM (diabetes mellitus) preventing use of dexamethasone in the perioperative period
  • * Cardiac arrhythmia
  • * History of AMI (acute myocardial infarction), stroke, seizure, liver failure
  • * Laboratory results showing platelets \<150,000, PT (prothrombin time) \>45, INR (international normalized ratio) \>1.2, seizure disorder

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Vanderbilt University Medical Center,

Shiayin F Yang, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

2025-02-01